Explainer video: Advise- Educating Patients about Addressing Glycemic and Weight Goals - Video

Talking about excess weight with people living with type 2 diabetes can be sensitive, but it is an important part of diabetes care. Evidence shows that modest and sustained weight loss of at least 5% of body weight improves glycemic control, blood pressure, and lipid levels. Greater weight loss, in the range of 10–15% or more, may even have disease-modifying effects. The ADA and EASD consensus reports highlight weight management as a key component of type 2 diabetes treatment.

Engaging patients in open, empathetic conversations about weight can help them see how weight loss connects not only to better blood glucose control but also to broader health outcomes and quality of life. It is essential to understand a patient’s weight history, assess their readiness for change, and set realistic, manageable goals together. Even small steps can empower patients, strengthen motivation, and improve overall diabetes management.

References:

1) American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(suppl 1):S113-S124.

2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966.

Disclaimer:

This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.

For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com. For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com. For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001 India Ph.: +91-124-4753000/01 | www.lilly.com/in.

PP code - PP-TR-IN-0779 | 06 October 2025

Eli Lilly and Company. All rights reserved.